ClinicalTrials.gg
CompletedNCT03829332Updated Feb 19, 2026Results posted

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 162 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
623
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 4 under way, 1 of them phase 3. lenvatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 14
623 · median 29
Started
2019
with 2 others
Phase 3
4 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
3 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 3 that started in 2019, is one of 4 in phase 3, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing lenvatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.

The primary study hypotheses are that: 1) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); and 2) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).

Read the detailed description

As of 30-Jul-2021, active participants, investigator, and sponsor personnel or delegate(s) involved in the treatment administration or clinical evaluation of the participants will be unblinded. Participants will discontinue lenvatinib and placebo, and participants who remain on treatment will receive open-label pembrolizumab only.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death-ligand 1 (PD-L1, PDL1)
  • programmed cell death-ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
  • Has Stage IV NSCLC (American Joint Committee on Cancer [AJCC 8th edition])
  • Has based on 1.1
  • Has tumor tissue that demonstrates programmed cell death-ligand 1 () expression in ≥1% of tumor cells (Tumor Proportion Score [TPS] ≥1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory
  • Has a of ≥3 months
  • Has an (ECOG) performance status of 0 or 1 within 7 days before the first dose of study treatment but before randomization
  • Male participants must agree to the following during the treatment period and for ≥7 days after the last dose of lenvatinib/matching placebo: 1) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR 2) Must agree to use unless confirmed to be azoospermic (vasectomized or secondary to medical cause)
  • Female participants are eligible to participate if not pregnant or breastfeeding, and ≥1 of the following applies: 1) Is not a woman of (WOCBP), OR 2) Is a WOCBP and is using a highly effective contraceptive method that has a low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for ≥120 days post pembrolizumab or ≥30 days post lenvatinib/matching placebo, whichever occurs last
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has known untreated central nervous system and/or carcinomatous meningitis
  • Has active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention
  • Has radiographic evidence of intratumoral cavitations, encasement, or invasion of a major blood vessel
  • Has a known history of an additional , except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for ≥3 years since initiation of that therapy. (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.)
  • Has an active disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
  • Has had an allogeneic tissue/solid organ transplant
  • Has a known history of (HIV) infection
  • Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease
  • Has a known history of or known active virus infection
  • Has a history of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral study drug absorption.
  • Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as a history of congestive heart failure greater than Class II, unstable angina, myocardial infarction, cerebrovascular accident/stroke, or cardiac arrhythmia associated with hemodynamic instability
  • Has not recovered adequately from any toxicity and/or complications from major surgery before starting study treatment
  • Has a known history of active tuberculosis (TB)
  • Has an active infection requiring systemic therapy
  • Has previously had a severe reaction to treatment with a monoclonal antibody or has a known sensitivity or intolerance to any component of lenvatinib or pembrolizumab
  • Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC
  • Has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137]) or has received lenvatinib as monotherapy or in combination with anti- programmed cell death protein (anti-PD-1) agents
  • Has received radiotherapy within 14 days before the first dose of study treatment or received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose of study treatment. (Note: Participants must have recovered from all radiation-related toxicities to ≤Grade 1, not require corticosteroids, and not have had radiation pneumonitis.)
  • Has a diagnosis of immunodeficiency or is receiving any form of therapy within 7 days before the first dose of study treatment
  • Is receiving systemic steroid therapy (doses >10 mg daily of prednisone equivalent) within 7 days before the first dose of study treatment
  • Has received a live or attenuated vaccine within 30 days before the first dose of study treatment
  • Has had major surgery within 3 weeks prior to first dose of study treatment
  • Has pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
623 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Lenvatinib

    Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Pembrolizumab + Placebo

    Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.

    Biological: Pembrolizumab · Drug: Placebo for lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • oral capsule

    Also known as: MK-7902, E7080, LENVIMA®

  • DrugPlacebo for lenvatinib

    oral capsule

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 was presented.

    Time frame: Up to approximately 25 months

  2. Overall Survival (OS)

    OS was defined as the time from date of randomization to date of death from any cause. OS was presented.

    Time frame: Up to approximately 25 months

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR as assessed by BICR per RECIST 1.1 is presented.

    Time frame: Up to approximately 25 months

  2. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE were reported

    Time frame: Through 90 days post last dose of study treatment (Up to approximately 27 months)

  3. Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE were reported.

    Time frame: Through last dose of study treatment (Up to approximately 24 months)

  4. Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score

    EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in GHS and QoL combined score was presented.

    Time frame: Baseline and Week 21

  5. Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in cough (EORTC QLQ-LC13 Item 31) score was presented.

    Time frame: Baseline and Week 21

  6. Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score

    The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-LC13 chest pain (Item 40) score was presented.

    Time frame: Baseline and Week 21

  7. Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score was presented.

    Time frame: Baseline and Week 21

  8. Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score was presented.

    Time frame: Baseline and Week 21

  9. Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score

    EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  10. Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 31). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  11. Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

    EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 40). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  12. Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  13. Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score

    EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.

    Time frame: Up to approximately 25 months

  14. Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)

    The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8; score range:1=Not at All to 4=Very Much). Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31; score range:1=Not at All to 4=Very Much ) and chest pain (Item 40, score range: 1=Not at All to 4=Very Much). The combined score of items 31, 40 and 8 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD in the composite endpoint of EORTC QLQ-LC13 Item 31, EORTC QLQ-LC13 Item 40, EORTC QLQ-C30 Item 8 scale score was presented, defined as the time to first onset of a ≥10point decrease from baseline in anyone of the three scale items. A longer TTD indicates better outcome.

    Time frame: Up to approximately 25 months

07

Results

Posted Jun 2, 2022

Participant flow

Of the 623 total participants randomized in the MK-7902-007 global study, 80 were also randomized in the China extension study for MK-7902-007 (NCT04676412).

Participant flow — Overall Study
MilestonePembrolizumab + LenvatinibPembrolizumab + Placebo
Started309314
Treated309312
Completed00
Not completed309314
Withdrew: Death225230
Withdrew: Lost to follow-up13
Withdrew: Physician decision10
Withdrew: Sponsor decision7172
Withdrew: Withdrawal by subject119

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 was presented.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)6.6 (6.1 to 8.2)4.2 (4.1 to 6.2)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.00624 · Hazard ratio (hr): 0.78 · 95% CI 0.64 to 0.95One-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.
PrimaryOverall Survival (OS)

OS was defined as the time from date of randomization to date of death from any cause. OS was presented.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Overall Survival (OS)14.1 (11.4 to 19.0)16.4 (12.6 to 20.6)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.79744 · Hazard ratio (hr): 1.10 · 95% CI 0.87 to 1.39One-sided p-value based on log-rank test stratified by ECOG, region, and baseline PD-L1 status.
SecondaryObjective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR as assessed by BICR per RECIST 1.1 is presented.

Time frame:
Up to approximately 25 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Percentage of ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)40.5 (34.9 to 46.2)27.7 (22.8 to 33.0)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Miettinen & Nurminen · p = 0.00037 · Percent difference: 12.8 · 95% CI 5.4 to 20.1One-sided p-value for testing. H0: difference in percent = 0 versus H1: difference in percent \> 0.
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE were reported

Time frame:
Through 90 days post last dose of study treatment (Up to approximately 27 months)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Experienced an Adverse Event (AE)306294
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE were reported.

Time frame:
Through last dose of study treatment (Up to approximately 24 months)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
ParticipantsPembrolizumab + LenvatinibPembrolizumab + Placebo
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)9841
SecondaryChange From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score

EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in GHS and QoL combined score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score-1.48 (-4.09 to 1.13)2.42 (-0.24 to 5.08)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Constrained longitudinal data analysis · p = 0.0262 · Difference in least square (ls) means: -3.90 · 95% CI -7.34 to -0.47Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG, region \& baseline PDL-1.
SecondaryChange From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score

The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in cough (EORTC QLQ-LC13 Item 31) score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score-9.53 (-12.94 to -6.13)-5.04 (-8.51 to -1.57)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.0461 (Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG, region \& baseline PDL-1.) · Difference in ls means: -4.50 · 95% CI -8.91 to -0.08
SecondaryChange From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score

The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-LC13 chest pain (Item 40) score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score-4.64 (-7.45 to -1.84)-3.55 (-6.42 to -0.68)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.5596 · Difference in ls means: -1.10 · 95% CI -4.78 to 2.59Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG, region \& baseline PDL-1.
SecondaryChange From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score-1.35 (-4.75 to 2.04)-0.47 (-3.94 to 3.00)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.7088 · Difference in ls means: -0.88 · 95% CI -5.49 to 3.74Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG, region \& baseline PDL-1.
SecondaryChange From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score was presented.

Time frame:
Baseline and Week 21
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score
Score on a scalePembrolizumab + LenvatinibPembrolizumab + Placebo
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score-6.73 (-9.35 to -4.10)-3.72 (-6.40 to -1.04)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · cLDA model · p = 0.1116 · Difference in ls means: -3.01 · 95% CI -6.71 to 0.70Two-sided p-value based on cLDA model with covariates for treatment by study visit interaction; stratified by ECOG, region \& baseline PDL-1.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score

EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined ScoreNA (14.1 to NA)NA (19.3 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.9601 · Hazard ratio (hr): 1.00 · 95% CI 0.75 to 1.33Two-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 31). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.0079 · Hazard ratio (hr): 0.61 · 95% CI 0.42 to 0.88Two-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score

EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 40). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale ScoreNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.7457 · Hazard ratio (hr): 1.06 · 95% CI 0.73 to 1.56Two-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Mean · Months
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale ScoreNA (NA to NA)NA (20.8 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.8122 · Hazard ratio (hr): 1.04 · 95% CI 0.75 to 1.44Two-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score

EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score18.8 (14.1 to NA)NA (20.0 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.1480 · Hazard ratio (hr): 1.24 · 95% CI 0.92 to 1.67Two-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.
SecondaryTime to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)

The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8; score range:1=Not at All to 4=Very Much). Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31; score range:1=Not at All to 4=Very Much ) and chest pain (Item 40, score range: 1=Not at All to 4=Very Much). The combined score of items 31, 40 and 8 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD in the composite endpoint of EORTC QLQ-LC13 Item 31, EORTC QLQ-LC13 Item 40, EORTC QLQ-C30 Item 8 scale score was presented, defined as the time to first onset of a ≥10point decrease from baseline in anyone of the three scale items. A longer TTD indicates better outcome.

Time frame:
Up to approximately 25 months
Reported as:
Median · Months
Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)
MonthsPembrolizumab + LenvatinibPembrolizumab + Placebo
Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)5.78 (2.79 to NA)NA (3.45 to NA)
Statistical analysis
  • Pembrolizumab + Lenvatinib vs Pembrolizumab + Placebo · Stratified Log Rank · p = 0.4068 · Hazard ratio (hr): 1.31 · 95% CI 0.70 to 2.46Two-sided p-value based on log-rank test stratified by ECOG, region and baseline PD-L1 status.

Adverse events

Collected over Up to approximately 61 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab229/309 (74.1%)192/309 (62.1%)296/309 (95.8%)
Placebo + Pembrolizumab232/314 (73.9%)118/312 (37.8%)275/312 (88.1%)
Most frequent serious events
Showing 10 of 228
Most frequent serious events
EventLenvatinib + PembrolizumabPlacebo + Pembrolizumab
PneumoniaInfections and infestations32/30917/312
DeathGeneral disorders13/3091/312
HaemoptysisRespiratory, thoracic and mediastinal disorders9/3092/312
DiarrhoeaGastrointestinal disorders8/3090/312
COVID-19 pneumoniaInfections and infestations8/3094/312
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/3098/312
Decreased appetiteMetabolism and nutrition disorders7/3090/312
PneumonitisRespiratory, thoracic and mediastinal disorders7/3093/312
PneumothoraxRespiratory, thoracic and mediastinal disorders7/3091/312
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/3096/312
Most frequent other events
Showing 10 of 50
Most frequent other events
EventLenvatinib + PembrolizumabPlacebo + Pembrolizumab
HypothyroidismEndocrine disorders127/30935/312
HypertensionVascular disorders122/30946/312
DiarrhoeaGastrointestinal disorders109/30939/312
ProteinuriaRenal and urinary disorders101/30936/312
Weight decreasedInvestigations83/30925/312
Decreased appetiteMetabolism and nutrition disorders77/30951/312
NauseaGastrointestinal disorders70/30942/312
AnaemiaBlood and lymphatic system disorders57/30968/312
Aspartate aminotransferase increasedInvestigations62/30932/312
Alanine aminotransferase increasedInvestigations60/30932/312

Baseline characteristics

All participants randomized.

Age, Continuous
Age, Continuous(years)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Mean64.6 ± 9.665.4 ± 8.865.0 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Female7990169
Male230224454
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
Hispanic or Latino323062
Not Hispanic or Latino266269535
Unknown or Not Reported111526
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
American Indian or Alaska Native7310
Asian103104207
Native Hawaiian or Other Pacific Islander000
Black or African American011
White188193381
More than one race336
Unknown or Not Reported81018
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
ECOG = 0110108218
ECOG = 1199206405
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline
Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
TPS = 1-49%172175347
TPS = ≥ 50%137139276
Geographic Region
Geographic Region(Participants)Pembrolizumab + LenvatinibPembrolizumab + PlaceboTotal
East Asia103104207
Non-East Asia206210416
08

Study locations

162 sites
  • Alaska Clinical Research Center ( Site 0511)
    Anchorage, Alaska 99503, United States
  • Ironwood Cancer & Research Centers ( Site 0541)
    Chandler, Arizona 85224, United States
  • CBCC Global Research, Inc. ( Site 0532)
    Bakersfield, California 93309, United States
  • Scripps Cancer Center ( Site 0521)
    La Jolla, California 92037, United States
  • Florida Hospital ( Site 0526)
    Orlando, Florida 32803, United States
  • Northwest Georgia Oncology Centers PC ( Site 0518)
    Marietta, Georgia 30060, United States
  • Illinois Cancer Care, PC ( Site 0557)
    Peoria, Illinois 61615, United States
  • Parkview Cancer Center ( Site 0542)
    Fort Wayne, Indiana 46845, United States
  • University of Kentucky School of Medicine & Hospitals ( Site 0517)
    Lexington, Kentucky 40536, United States
  • Anne Arundel Medical Center Oncology and Hematology ( Site 0514)
    Annapolis, Maryland 21401, United States
  • Munson Medical Center ( Site 0512)
    Traverse City, Michigan 49684, United States
  • Park Nicollet Frauenshuh Cancer Center ( Site 0554)
    Saint Louis Park, Minnesota 55426, United States
  • University of Missouri Health Care ( Site 0555)
    Columbia, Missouri 65212, United States
  • Billings Clinic Cancer Center ( Site 0508)
    Billings, Montana 59101, United States
  • Cone Health Cancer Center at Alamance Regional ( Site 0527)
    Greensboro, North Carolina 27403, United States
  • Genesis Cancer Care Center ( Site 0559)
    Zanesville, Ohio 43701, United States
  • Oregon Health Sciences University ( Site 0544)
    Portland, Oregon 97239, United States
  • Central Texas Veterans Healthcare System ( Site 0533)
    Temple, Texas 76504, United States
  • Orange Health Services ( Site 0002)
    Orange, New South Wales 2800, Australia
  • Wollongong Private Hospital ( Site 0005)
    Wollongong, New South Wales 2500, Australia
  • The Prince Charles Hospital ( Site 0011)
    Chermside, Queensland 4032, Australia
  • Ballarat Oncology and Haematology Services ( Site 0008)
    Wendouree, Victoria 3355, Australia
  • St John of God Murdoch Medical Clinic ( Site 0001)
    Perth, Western Australia 6150, Australia
  • Cross Cancer Institute ( Site 0400)
    Edmonton, Alberta T6G 1Z2, Canada
  • Lions Gate Hospital ( Site 0407)
    North Vancouver, British Columbia V7L 2L7, Canada
  • William Osler Health System (Brampton Civic Hospital) ( Site 0402)
    Brampton, Ontario L6R 3J7, Canada
  • Windsor Regional Cancer Program ( Site 0404)
    Windsor, Ontario N8W 2X3, Canada
  • McGill University Health Centre ( Site 0418)
    Montreal, Quebec H4A 3J1, Canada
  • Beijing Chest Hospital Capital Medical University ( Site 0111)
    Beijing, Anhui 101149, China
  • Anhui Provincial Hospital ( Site 0108)
    Hefei, Anhui 230001, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0113)
    Hefei, Anhui 230088, China
  • Peking Union Medical College Hospital ( Site 0105)
    Beijing, Beijing Municipality 100006, China
  • Beijing Cancer Hospital ( Site 0102)
    Beijing, Beijing Municipality 100036, China
  • Xiangya Hospital of Central South University ( Site 0115)
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital ( Site 0104)
    Changsha, Hunan 410013, China
  • Jiangsu Cancer Hospital ( Site 0101)
    Nanjing, Jiangsu 210009, China
  • The First Hospital of Jilin University ( Site 0110)
    Changchun, Jilin 130021, China
  • Zhongshan Hospital Fudan University ( Site 0100)
    Shanghai, Shanghai Municipality 200433, China
  • Shanghai Chest Hospital ( Site 0112)
    Shanghai, Shanghai Municipality 230000, China
  • 1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 0103)
    XiAn, Shanxi 710061, China
  • West China Hospital of Sichuan University ( Site 0117)
    Chengdu, Sichuan 510115, China
  • The First Affiliated Hospital Zhejiang University ( Site 0106)
    Hangzhou, Zhejiang 310003, China
  • Hangzhou First People's Hospital ( Site 0109)
    Hangzhou, Zhejiang 310006, China
  • 2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0114)
    Hangzhou, Zhejiang 310009, China
  • Zhejiang Cancer Hospital ( Site 0116)
    Hangzhou, Zhejiang 310022, China
  • Hospital General de Medellin Luz Castro de Gutierrez ( Site 0368)
    Medellín, Antioquia 050015, Colombia
  • Fundacion Centro de Investigacion Clinica CIC ( Site 0366)
    Medellín, Antioquia 050021, Colombia
  • Biomelab S A S ( Site 0365)
    Barranquilla, Atlántico 080002, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 0374)
    Valledupar, Cesar Department 200001, Colombia
  • Oncomedica S.A. ( Site 0372)
    Montería, Departamento de Córdoba 230002, Colombia
  • Centro Medico Imbanaco de Cali S.A ( Site 0369)
    Cali, Valle del Cauca Department 760023, Colombia
  • AS Ida-Tallinna Keskhaigla ( Site 0161)
    Tallinn, Harju 11312, Estonia
  • SA Pohja-Eesti Regionaalhaigla ( Site 0162)
    Tallinn, Harju 13419, Estonia
  • SA Tartu Ulikooli Kliinikum ( Site 0160)
    Tartu, Tartu 50406, Estonia
  • CHU Jean Minjoz ( Site 0167)
    Besançon, Doubs 25000, France
  • Institut Curie - Centre Rene Huguenin ( Site 0181)
    Saint-Cloud, Hauts-de-Seine 92210, France
  • ICM Val D Auerelle ( Site 0177)
    Montpellier, Herault 34090, France
  • CHU de Grenoble - Hopital Michallon ( Site 0169)
    La Tronche, Isere 38700, France
  • Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0185)
    Saint-Herblain, Loire-Atlantique 44805, France
  • Centre Hospitalier de la Cote Basque ( Site 0173)
    Bayonne, Pyrenees-Atlantiques 64109, France
  • CHU de Rouen ( Site 0174)
    Rouen, Seine-Maritime 76000, France
  • CHU Amiens Sud ( Site 0182)
    Amiens, Somme 80054, France
  • Centre hospitalier Toulon Sainte-Musse ( Site 0172)
    Toulon, Var 83056, France
  • Institut Curie ( Site 0166)
    Paris, 75248, France
  • Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0207)
    Gyula, Bekes County 5700, Hungary
  • Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0202)
    Miskolc, Borsod-Abauj Zemplen county 3529, Hungary
  • CRU Hungary KFT ( Site 0209)
    Miskolc, Borsod-Abauj Zemplen county 3529, Hungary
  • Petz Aladar Megyei Oktato Korhaz ( Site 0213)
    Győr, Győr-Moson-Sopron 9024, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0203)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Tudogyogyintezet Torokbalint ( Site 0205)
    Törökbálint, Pest County 2045, Hungary
  • Semmelweis Egyetem ( Site 0210)
    Budapest, 1083, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0217)
    Kaposvár, 7400, Hungary
  • Bnei Zion Medical Center ( Site 0227)
    Haifa, Heifa 3339419, Israel
  • Sheba Medical Center ( Site 0220)
    Ramat Gan, Tel Aviv 5266202, Israel
  • Soroka Medical Center ( Site 0222)
    Beersheba, 8457108, Israel
  • Rambam Medical Center ( Site 0223)
    Haifa, 3109601, Israel
  • Meir Medical Center ( Site 0221)
    Kfar Saba, 4428132, Israel
  • Rabin Medical Center ( Site 0224)
    Petah Tikva, 4941492, Israel
  • Sourasky Medical Center ( Site 0225)
    Tel Aviv, 6423906, Israel
  • Barzilai Medical Center ( Site 0226)
    Ashkelon, Ḥeifā 7830604, Israel
  • Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 0233)
    Rome, Lazio 00185, Italy
  • Presidio Ospedaliero San Vincenzo ( Site 0231)
    Taormina, Messina 98039, Italy
  • Centro di Riferimento Oncologico CRO ( Site 0235)
    Aviano, Pordenone 33081, Italy
  • Azienda Ospedaliera San Giuseppe Moscati ( Site 0234)
    Avellino, 83100, Italy
  • Universita Magna Grecia ( Site 0230)
    Catanzaro, 88100, Italy
  • A.O. Universitaria Careggi ( Site 0236)
    Florence, 50134, Italy
  • Ospedale Santa Maria delle Croci ( Site 0232)
    Ravenna, 48121, Italy
  • Policlinico Gemelli di Roma ( Site 0237)
    Roma, 00168, Italy
  • Aichi Cancer Center Hospital ( Site 0018)
    Nagoya, Aichi-ken 464-8681, Japan
  • Kurume University Hospital ( Site 0025)
    Kurume, Fukuoka 830-0011, Japan
  • Hyogo Cancer Center ( Site 0021)
    Akashi, Hyōgo 673-8558, Japan
  • Kanagawa Cardiovascular and Respiratory Center ( Site 0026)
    Yokohama, Kanagawa 236-0051, Japan
  • Kanagawa Cancer Center ( Site 0023)
    Yokohama, Kanagawa 241-8515, Japan
  • Miyagi Cancer Center ( Site 0028)
    Natori-shi, Miyagi 981-1293, Japan
  • Sendai Kousei Hospital ( Site 0022)
    Sendai, Miyagi 980-0873, Japan
  • National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0027)
    Sakai, Osaka 591-8555, Japan
  • Kindai University Hospital ( Site 0017)
    Sayama, Osaka 589-8511, Japan
  • National Hospital Organization Kyushu Medical Center ( Site 0015)
    Fukuoka, 810-8563, Japan
  • Kyushu University Hospital ( Site 0030)
    Fukuoka, 812-8582, Japan
  • Okayama University Hospital ( Site 0020)
    Okayama, 700-8558, Japan

Showing the first 100 of 162 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yang JC, Han B, De La Mora Jimenez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csoszi T. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncol. 2024 Jun;19(6):941-953. doi: 10.1016/j.jtho.2023.12.023. Epub 2023 Dec 29. PubMed 38159809 ↗
  • Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PubMed 33300372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in May 2021, 26 months.

Results were first posted in Jun 2022, 1 year after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 26 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2019
First posted
Feb 4, 2019
StartActual
Mar 13, 2019
Primary completionActual
May 19, 2021
CompletionActual
Apr 24, 2024
Results first posted
Jun 2, 2022
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03829332
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Feb 4, 2019
Start date
Mar 13, 2019
Primary completion
May 19, 2021
Completion
Apr 24, 2024
Results posted
Jun 2, 2022
Last update
Feb 19, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion